Management Committee
Prof. Michal Lotem
The Founder and Head of the Hadassah Cancer Research Institute, Professor Michal Lotem is an international expert in skin cancer and clinical oncology, driving cutting-edge scientific innovation at the HCRI since its inception in 2019. Her vision for HCRI is to investigate the nature of various cancers and enable HRCI’s physicians, scientists and researchers to develop new and personalized ways to manipulate the immune system to cure cancer, with the goal of eradicating cancer.
Prof. Rotem Karni
Prof. Rotem Karni is an internationally recognized expert in RNA biology and cancer research. His work focuses on alternative splicing, RNA-binding proteins, and RNA-based therapeutic strategies in oncology. He currently works at the Perelman School of Medicine, University of Pennsylvania where he leads a multidisciplinary lab focused on uncovering splice-factor misregulation in tumors, engineering antisense oligonucleotides and small molecules to reprogram pathogenic splicing, and exploiting m^6A RNA modifications to develop innovative cancer immunotherapies and targeted treatments.
Amalia Herszkowicz
Amalia is an experienced executive specializing in leading scientific breakthroughs through “first-in-human” clinical trials. As COO of the Hadassah Cancer Research Institute, she leverages her C-Level experience and entrepreneurial skills. Previously, she led companies developing COVID-19 treatments and pan-cancer screening tests. She has a 20-year track record of translating innovation into marketable solutions across diagnostics, therapeutics, and medical devices.
